Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
IMPORTANT: This compound is currently on the World Anti-Doping Agency (WADA) prohibited list. Competitive athletes face sanctions for use including in retirement testing programs. Verify current WADA status with your sport's governing body before any research involvement.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.
The Wolverine Stack: BPC-157 + TB-500 Combined Protocol — the full combined injury recovery guide.
TB-500 is a synthetic 17-amino acid fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein found throughout the human body. It works by sequestering free G-actin monomers, promoting actin polymerization, and enhancing cell migration into injured tissue. Research supports its use for tissue repair, wound healing, and inflammation modulation. The peptide has a half-life of approximately 10–14 days and is typically dosed at 2–2.5 mg twice weekly during a loading phase (4–6 weeks), followed by maintenance dosing of 2 mg once weekly.
TB-500 vs. Thymosin Beta-4: Understanding the Difference
Thymosin Beta-4 (Tβ4) is the full, naturally occurring 43-amino acid protein discovered by Allan Goldstein and colleagues in the 1970s. It is synthesized primarily in the thymus gland and is present in nearly every cell throughout the human body. The protein plays fundamental roles in cell migration, immune regulation, and tissue repair across multiple physiological systems.
TB-500 is the synthetic fragment — specifically a 17-amino acid peptide that corresponds to amino acids 17–23 of the full Tβ4 sequence, often denoted as the Ac-SDKP sequence. This fragment contains what researchers believe to be the actin-binding domain most responsible for the healing and anti-inflammatory effects observed in clinical studies.
Some research uses the full 43-amino acid Tβ4 protein (particularly in cardiac repair studies), while the peptide research community and most commercial products refer to TB-500 when discussing the shorter synthetic fragment. The two are not interchangeable — they differ in molecular weight, half-life, tissue distribution, and activity profile. Full-length Tβ4 has a shorter half-life and different pharmacokinetics compared to the TB-500 fragment.
Key structural differences include:
- Molecular weight: Full Tβ4 is ~4,979 Da; TB-500 fragment is ~494 Da, making it much smaller and potentially easier to synthesize and deliver.
- Half-life: TB-500 has a measured half-life of approximately 10–14 days, significantly longer than the full Tβ4 protein, which circulates with a much shorter window.
- Activity: Both contain the actin-binding domain, but the TB-500 fragment may have different biodistribution and receptor interactions due to its reduced size.
- Clinical use: The full Tβ4 protein is used in some clinical settings (particularly cardiac repair research), while TB-500 is the dominant form in the research peptide community.
How TB-500 Works: Mechanism of Action
TB-500's healing effects operate through several interconnected mechanisms:
Actin Sequestration and Cell Migration
The primary mechanism centers on TB-500's ability to sequester free G-actin monomers — the unpolymerized form of actin that exists in the cytoplasm. By binding G-actin, TB-500 promotes the polymerization of actin into filaments (F-actin), which are essential for cell motility. This enhanced actin dynamics makes fibroblasts, endothelial cells, and other repair-related cells more mobile, allowing them to migrate more efficiently into injured tissue. This increased cell migration is critical for wound closure and tissue remodeling.
Inflammation Modulation via NF-κB
TB-500 inhibits the NF-κB (nuclear factor kappa B) signaling pathway, a central regulator of inflammatory responses. By downregulating NF-κB activity, TB-500 reduces the production of pro-inflammatory cytokines (such as TNF-α and IL-6) at the injury site. This anti-inflammatory effect helps shift the tissue environment from an acute inflammatory state toward a tissue-remodeling state, accelerating the transition from inflammation to healing.
Angiogenesis and Vascular Remodeling
TB-500 promotes angiogenesis — the formation of new blood vessels — by upregulating growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Increased blood flow to injured tissue delivers oxygen, nutrients, and immune cells necessary for repair, while also removing metabolic waste products. Enhanced vascular perfusion is particularly important for tendon and ligament healing, which are relatively avascular tissues.
Stem Cell Activation and Differentiation
Research suggests TB-500 stimulates stem cell recruitment and differentiation, particularly in the context of cardiac and skeletal muscle repair. By promoting stem cell activation and their migration to injury sites, TB-500 may enhance the tissue's intrinsic regenerative capacity.
These mechanisms have been demonstrated in in vitro and animal models, with the most robust clinical evidence coming from wound healing and cardiac injury studies. However, human clinical trials remain limited, and most of the mechanism data is extrapolated from basic research and small animal studies.
Clinical Research Evidence
TB-500 has a deeper research foundation than most peptides in the community toolkit. Here is what the evidence actually shows:
Wound Healing: Sosne et al. and Dermal Repair
Some of the earliest and most compelling research on Thymosin Beta-4 and its fragments comes from corneal wound healing studies. Sosne et al. (2002–2010) conducted multiple studies demonstrating that Tβ4 (and by extension, the TB-500 fragment) significantly accelerates corneal epithelial wound healing. Topical application of Tβ4 to corneal abrasions reduced healing time and improved re-epithelialization rates in animal models and small human studies. The proposed mechanism involves enhanced cell migration into the wound bed and reduced inflammation.
Malinda et al. (1999) demonstrated that Tβ4 promotes dermal wound healing in mice through increased angiogenesis and fibroblast migration. Tissue sections from Tβ4-treated wounds showed earlier re-epithelialization, increased collagen deposition, and accelerated wound closure compared to controls.
Cardiac Repair: Bock-Marquette et al. and MI Recovery
Bock-Marquette et al. (2004) published landmark research showing that full-length Thymosin Beta-4 significantly improves cardiac function following myocardial infarction (MI) in mice. Tβ4-treated animals showed:
- Reduced infarct size: Smaller scar tissue formation after MI.
- Improved ejection fraction: Better overall cardiac contractility and output.
- Enhanced angiogenesis: More new blood vessel formation in the damaged region.
- Increased stem cell activation: Mobilization of epicardial progenitor cells into the injured myocardium.
This research opened the door to investigating Tβ4 for human cardiac repair, leading to clinical trials examining its safety and efficacy in post-MI recovery.
Epicardial Progenitor Activation: Smart et al.
Smart et al. (2007) demonstrated that Thymosin Beta-4 activates epicardial progenitor cells (EPCs) and promotes their migration into damaged cardiac tissue. This study was critical in showing that Tβ4 operates not just through actin dynamics, but also by mobilizing the heart's own stem cell populations to facilitate repair.
The strongest human data for Tβ4 comes from ophthalmology (corneal healing) and limited cardiac trials. Evidence for TB-500 specifically in musculoskeletal healing (tendon, ligament, muscle) in humans is largely anecdotal and extrapolated from animal studies. Community-reported results are favorable, but high-quality randomized controlled trials in human athletes or patients with sports injuries are sparse.
TB-500 vs. BPC-157: Key Differences and When to Use Each
TB-500 and BPC-157 are often compared because they are complementary — both support tissue healing, but through different mechanisms and with different pharmacokinetics. Understanding the distinction is critical for rational protocol design.
| Property | BPC-157 | TB-500 |
|---|---|---|
| Origin | Fragment of Body Protection Compound (endogenous peptide) | Fragment of Thymosin Beta-4 (43-aa protein) |
| Amino Acid Length | 15 amino acids | 17 amino acids (Ac-SDKP domain) |
| Half-life | ~2–3 hours | ~10–14 days |
| Primary Administration Route | Oral (sublingually) or subcutaneous | Subcutaneous (systemically distributed) |
| Primary Mechanisms | Angiogenesis, growth factor upregulation, GI barrier repair, local protection | Actin sequestration, cell migration, inflammation modulation (NF-κB), systemic angiogenesis, stem cell activation |
| GI Tract Activity | Highly active; supports mucosal barrier, increases blood flow | Not primarily targeted to GI tract |
| Distribution | Local action at site of application; some systemic absorption | Systemic; distributes widely throughout body |
| Strength for Muscle/Tendon Repair | Moderate; supports healing but less targeted to actin dynamics | Strong; directly enhances cell migration and actin polymerization |
| Strength for Inflammation | Good; local anti-inflammatory and growth factor upregulation | Strong; systemic NF-κB inhibition and anti-inflammatory modulation |
| Dosing Frequency | Often 1–2x daily (due to short half-life) | 1–2x weekly loading; 1x weekly maintenance (due to long half-life) |
| Time to Effect | Hours to days | Days to weeks (slower onset, longer duration) |
| Best Use Case | GI issues, local tendon/ligament damage, acute injury in first days | Systemic healing, chronic injuries, widespread tissue damage, long-term support |
In summary: BPC-157 is a local, fast-acting peptide excellent for acute injury and GI support. TB-500 is a systemic, long-acting peptide ideal for chronic or widespread tissue damage requiring sustained repair signaling. Many users find them complementary rather than competitive.
Dosing Protocols
TB-500 dosing follows a well-established loading-and-maintenance framework based on community experience and the peptide's long half-life (~10–14 days).
Standard Loading Phase
- Dose: 2–2.5 mg injected subcutaneously
- Frequency: 2x per week (e.g., Monday and Thursday)
- Duration: 4–6 weeks
- Total loading dose: Approximately 16–30 mg over the loading period
The loading phase builds up steady-state concentrations and initiates the cellular signaling cascades necessary for healing acceleration.
Maintenance Phase
- Dose: 2 mg injected subcutaneously
- Frequency: 1x per week (e.g., Monday)
- Duration: 4–8 additional weeks (optional)
Maintenance dosing sustains the therapeutic effect without over-accumulation. Many users skip maintenance and simply cycle off after the loading phase, resuming when needed for a new injury or at the start of a new training cycle.
Acute Injury Protocols
For acute injuries (recent sprains, tears, post-surgical), some protocols recommend:
- Dose: 5 mg per week split across 2–3 injections (e.g., 2.5 mg on days 1 and 4, or 1.67 mg on days 1, 3, and 5)
- Duration: 4 weeks, then step down to standard loading
The rationale is that acute injury benefits from a higher initial tissue concentration, while sustained healing uses less aggressive dosing.
Reconstitution and Storage
TB-500 is supplied as lyophilized (freeze-dried) powder. Proper reconstitution is critical for stability and accuracy:
- Reconstitution solvent: Bacteriostatic water (0.9% sodium chloride solution with benzyl alcohol) or sterile water for injection
- Typical concentration: 2 mg/2 mL (1 mg/mL) or 5 mg/5 mL (1 mg/mL)
- Mixing method: Gently add solvent to powder; do not shake vigorously, as this can denature the peptide. Let it sit for a few minutes to fully dissolve.
- Refrigeration: Store reconstituted TB-500 at 2–8°C for up to 3 weeks, or at room temperature for up to 1 week if necessary.
- Freezing: Reconstituted TB-500 can be frozen at −20°C for extended storage, though this may slightly reduce stability over months.
Always use sterile technique when reconstituting and injecting TB-500. Use new, sterile 29–31 gauge insulin syringes for subcutaneous injection, and practice aseptic injection protocol to minimize infection risk. Rotate injection sites to avoid lipohypertrophy or scarring.
Side Effects and Safety Profile
TB-500 is generally well-tolerated, with a favorable safety profile based on available research and community reports. However, some potential side effects have been documented:
Common Reported Side Effects
- Headaches: Reported by some users, typically mild and transient. May be dose-related or reflect systemic adaptation.
- Lethargy or fatigue: A small percentage of users report mild fatigue, particularly during the first 1–2 weeks of loading. Usually resolves with continued use.
- Temporary hair shedding: Anecdotal reports of increased hair shedding or telogen effluvium during TB-500 use. The mechanism is unclear, but may be related to systemic remodeling. Hair typically regrows after discontinuation.
- Appetite changes: Some users report increased or decreased appetite; typically mild and inconsistent.
- Flushing or local injection site reactions: Mild redness or warmth at injection sites; rare and usually resolves quickly.
Theoretical Concerns
- Growth factor effects: Because TB-500 upregulates angiogenesis and cell proliferation, there is a theoretical concern about supporting uncontrolled cell growth in users with existing cancers or pre-malignant conditions. This concern is largely theoretical; no clinical evidence of malignancy promotion exists, but caution is warranted in high-risk populations.
- Immune modulation: TB-500's anti-inflammatory effects may theoretically impair immune responses in certain contexts, though this has not been clinically demonstrated.
Safety Profile Summary
In the available research literature and community experience, TB-500 has not produced serious adverse events. Most side effects are mild, transient, and resolve upon discontinuation. The peptide's long history of use in cardiac and ophthalmology research, combined with favorable tolerability data, supports its reputation as one of the safer peptides. However, as with all research compounds, long-term safety in humans is not fully established.
TB-500 is not FDA-approved for human use and is sold as a research chemical. Users should be aware that long-term safety, optimal dosing ranges for specific conditions, and drug interactions have not been comprehensively studied in human populations. Consult a healthcare professional before use.
WADA Prohibited Substance Status and Sport
TB-500 is explicitly prohibited by the World Anti-Doping Agency (WADA) under the S2 Peptide Hormone category on the WADA Prohibited List (effective since 2010). Any athlete competing in WADA-regulated sports — including Olympic sports, professional cycling, track and field, swimming, and many others — cannot use TB-500 without facing potential sanctions.
Detection Methods
TB-500 can be detected in both urine and blood samples using modern analytical techniques:
- Mass spectrometry (MS/MS): The primary detection method. TB-500's distinctive amino acid sequence can be identified via intact peptide analysis or after peptide degradation.
- Immunoassay: Some anti-doping labs employ immunoassays targeting specific epitopes of TB-500.
- Detection window: Due to TB-500's ~10–14 day half-life, the peptide can be detected in urine and blood for 2–4 weeks or longer after the last injection, depending on dose and test sensitivity.
Consequences of Use in Sport
Athletes who test positive for TB-500 face:
- Provisional suspension pending investigation
- Disqualification from competition
- Forfeiture of medals and prizes
- Ineligibility bans ranging from 2–4 years or lifetime, depending on the sport's rules and the athlete's history
- Mandatory education or therapeutic use exemption (TUE) applications (which are rarely granted for TB-500)
Bottom line for athletes: TB-500 is incompatible with competitive sport at any level where WADA rules apply. Non-tested recreational athletes or those in non-WADA sports may have different considerations, but the legal and regulatory risks should be carefully weighed.
Stacking TB-500 with BPC-157: The "Wolverine Stack"
Combining TB-500 with BPC-157 is one of the most popular stacking protocols in the peptide community, often called the "Wolverine Stack" in reference to the fictional character's rapid healing ability. This combination is appealing because the two peptides operate through complementary mechanisms.
Rationale for Stacking
TB-500 drives systemic healing via actin dynamics and cell migration. Its long half-life allows for sustained signaling, and its NF-κB inhibition creates a pro-healing inflammatory environment.
BPC-157 drives local angiogenesis and growth factor upregulation. Its short half-life means rapid local action, and it is particularly effective at restoring gastrointestinal barrier function and supporting local tissue vascularity.
Together, they create a two-pronged approach:
- Systemic support (TB-500): Enhanced cell migration, actin polymerization, and systemic inflammation modulation.
- Local support (BPC-157): Intensified blood vessel formation, growth factor release, and tissue-specific healing responses.
Typical Wolverine Stack Protocol
- TB-500: 2–2.5 mg subcutaneously 2x per week for 4–6 weeks (loading), then 2 mg 1x per week (maintenance)
- BPC-157: 250–500 mcg (0.25–0.5 mg) subcutaneously 1x per day or 5 mg orally 1–2x per day, running throughout the TB-500 cycle
- Duration: 6–10 weeks total, often coinciding with the injury recovery timeline
Community Reports and Evidence
Users report synergistic healing benefits, particularly for severe or chronic injuries. Subjective improvements in pain reduction, mobility restoration, and recovery speed appear to exceed what would be expected from either peptide alone. However, no controlled clinical trials directly compare the Wolverine Stack to monotherapy with either peptide, so these observations remain anecdotal.
The theoretical basis for stacking is sound: different mechanisms, complementary timelines, and local + systemic coverage should, in principle, yield superior outcomes. However, rigorous evidence is lacking. Users should understand that stacking increases cost, injection frequency, and potential for unforeseen interactions, even though no serious adverse interactions have been documented.
Bottom Line
TB-500 stands apart in the peptide landscape for having a relatively robust research foundation. The clinical evidence for wound healing, cardiac repair, and angiogenesis is stronger than for most compounds in the community toolkit. Its long half-life, favorable safety profile, and complementary mechanism to BPC-157 make it a rational choice for users pursuing injury recovery and healing optimization.
Key takeaways:
- Mechanism: TB-500 works through actin sequestration, enhanced cell migration, NF-κB-mediated inflammation control, and angiogenesis promotion.
- Research: The strongest evidence comes from wound healing and cardiac repair; musculoskeletal data in humans is limited.
- Dosing: Loading phase of 2–2.5 mg 2x weekly for 4–6 weeks, followed by optional 2 mg weekly maintenance.
- Safety: Generally well-tolerated; the most common side effects (headache, fatigue) are mild and transient.
- Sport: WADA prohibited; incompatible with competitive athletics under WADA jurisdiction.
- Stacking: Combining with BPC-157 offers complementary mechanisms and is widely reported to enhance healing outcomes, though rigorous evidence is lacking.
- Not medical advice: TB-500 is a research compound not approved for human use. Consult a healthcare professional before considering use.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions
TB-500 is a synthetic 17-amino acid fragment of the full 43-amino acid Thymosin Beta-4 (Tβ4) protein. The fragment corresponds to amino acids 17–23 (the Ac-SDKP domain), which research suggests contains the actin-binding region responsible for most healing effects. TB-500 has a longer half-life (~10–14 days) than full-length Tβ4 and differs in molecular weight and tissue distribution. The full protein is used in some clinical trials, while TB-500 dominates the research peptide community.
TB-500 operates through multiple mechanisms: it sequesters free G-actin to enhance cell migration, inhibits NF-κB signaling to reduce inflammation, promotes angiogenesis (new blood vessel formation) by upregulating VEGF and bFGF, and activates stem cells to contribute to tissue repair. The combined effect accelerates the transition from acute inflammation to tissue remodeling and accelerates closure and restoration of injured tissue.
The standard protocol includes a loading phase of 2–2.5 mg injected subcutaneously 2x per week for 4–6 weeks, followed by optional maintenance dosing of 2 mg once weekly for 4–8 additional weeks. For acute injuries, doses can be increased to 5 mg per week split across 2–3 injections. Reconstitution uses bacteriostatic water at 1 mg/mL, and reconstituted TB-500 is stored at 2–8°C for up to 3 weeks.
TB-500 is generally well-tolerated with a favorable safety profile. Reported side effects are typically mild and transient: headaches, lethargy or fatigue (usually in the first 1–2 weeks), and occasional temporary hair shedding. Flushing or local injection site reactions are rare. There is a theoretical concern about growth factor effects in users with existing cancers, but no clinical evidence of malignancy promotion exists. Long-term human safety data is limited, as TB-500 is not FDA-approved for human use.
Yes, TB-500 is explicitly prohibited by the World Anti-Doping Agency (WADA) under the S2 Peptide Hormone category since 2010. It is detectable in urine and blood for 2–4 weeks or longer after injection due to its long half-life. Athletes who test positive face disqualification, medal forfeiture, and ineligibility bans of 2–4 years or longer. TB-500 is incompatible with competitive sport under WADA jurisdiction.
Yes, stacking TB-500 with BPC-157 is common and supported by theoretical reasoning. The combination, called the "Wolverine Stack," combines TB-500's systemic, long-acting healing effects with BPC-157's local, short-acting growth factor and angiogenesis support. Community reports suggest synergistic healing benefits, particularly for severe or chronic injuries, though controlled clinical evidence is lacking. Typical protocols run both peptides together for 6–10 weeks, with TB-500 on a 2x weekly loading schedule and BPC-157 daily or 1x daily.
TB-500 has a slower onset than BPC-157 due to its long half-life and the time required for cellular signaling cascades to build. Most users report noticing improvements in pain, mobility, or healing within 2–4 weeks of starting the loading phase. Full benefits are typically apparent by 6–8 weeks of consistent use. The longer half-life means TB-500 reaches steady-state concentrations over 3–4 weeks, so patience is required before expecting maximal effects.
The strongest evidence comes from Sosne et al.'s corneal wound healing studies, Malinda et al.'s dermal wound healing work, and Bock-Marquette et al.'s groundbreaking cardiac repair research following myocardial infarction. Smart et al. demonstrated TB-500's activation of epicardial progenitor cells. These studies were conducted in animal models or limited human trials. Evidence for TB-500 specifically in musculoskeletal healing (tendon, ligament, muscle) in humans is largely anecdotal and extrapolated from animal research. Controlled human trials remain sparse.
TB-500 and BPC-157 are complementary rather than competitive. TB-500 is systemic and long-acting (~10–14 day half-life), excelling at actin-mediated cell migration and systemic inflammation control. BPC-157 is local and short-acting (~2–3 hour half-life), excelling at angiogenesis, growth factor upregulation, and GI tract support. BPC-157 is more effective for acute injury and oral use; TB-500 is more effective for chronic or widespread tissue damage requiring sustained healing signaling. Many users find them work best together.
Anecdotal reports describe temporary hair shedding or telogen effluvium during TB-500 use. The mechanism is unclear, but may relate to systemic remodeling or stress signaling. Hair typically regrows after discontinuation. No long-term adverse effects have been documented in the available literature. However, as TB-500 is not FDA-approved and long-term human safety studies are limited, potential effects in extended use are not fully characterized. Users should monitor for any unexpected changes and discuss concerns with a healthcare provider.